Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 5
---
 be exercised at any time until all of the Pre-Funded
Warrants are exercised in full.

We are registering up to 5,923,377,900,000 Ordinary Shares (in the form of Depositary Shares) under this prospectus, including Ordinary Shares (in the form of Depositary Shares) issuable if the holders of the Series L Warrants elect the zerocash exercise price option. As of December 1, 2025, there were 68,178,708,922 Ordinary Shares outstanding. If all of the Ordinary Shares (represented by Depositary Shares) offered under this prospectus were issued and outstanding as of December 1, 2025, such shares would represent approximately 98.9% of the total number of Ordinary Shares issued and outstanding.

The Depositary Shares and Pre-Funded Warrants, and the accompanying Series L Warrants, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Pursuant to the registration statement related to this prospectus, we are also registering the Depositary Shares issuable upon exercise of the Series L Warrants and Pre-Funded Warrants included in the Units and Pre-Funded Units offered hereby.

For each Pre-Funded Unit we
sell (without regard to any limitation on exercise set forth therein), the number of Units we are offering will be decreased on a one-for-one
basis. Because a Series L Warrant is being sold together in this offering with each Depositary Share and, in the alternative, each Pre-Funded
Warrant to purchase one Depositary Share, the number of Series L Warrants sold in this offering will not change as a result of a change
in the mix of the Depositary Shares and Pre-Funded Warrants sold.

Our
Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.”
On December 5, 2025, the last reported sale price of our Depositary Shares on the NASDAQ
Capital Market was $5.04 per share. All Depositary Share, Pre-Funded Warrant and Series L
Warrant numbers are based on an assumed combined public offering price of $5.09 per
Unit, which is based upon the closing price of our Depositary Shares on the NASDAQ Capital
Market on December 4, 2025. The actual public offering price will be determined through negotiation
between us and the placement agent in the offering and may be at a